Pharming announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.
CEO Sijmen de Vries will look back at 2019 and the recently published full year financial results.
Pharming announces that it has been included in the Euronext Amsterdam Midkap index (AMX).
Today Pharming announced it has also received US Food and Drug Administration (FDA) approval of Pharming’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead product, RUCONEST®.
The Company will hold a conference call at 13.00 CET/07.00 EST today. Dial in details can be found on page 12 of the press release.
Pharming Group today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.
Pharming announces today the placement of €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The offer was fully subscribed. The Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, South Africa and Japan.
Highlights • Replaces and repays the loan facility with Orbimed • Accelerates expansion of production and commercial capability, including the new territories reacquired from Sobi • Allows Pharming to extend its debt maturity profile through the period of development of its existing pipeline
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.
